<PAGE>
<TABLE>
<CAPTION>
- -------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION ----------------------------
FORM 3 WASHINGTON, D.C. 20549 OMB APPROVAL
- -------- ----------------------------
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES OMB Number: 3235-0104
Expires: September 30, 1998
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Estimated average burden
Section 17(a) of the Public Utility Holding Company Act of 1935 or hours per response .... 0.5
(Print or Type Responses) Section 30(f) of the Investment Company Act of 1940 ----------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
<S><C>
1. Name and Address of Reporting Person* 2. Date of Event Re- 4. Issuer Name AND Ticker or Trading Symbol
quiring Statement
(Month/Day/Year)
BVF Partners L.P. December 16, 1999 Autoimmune Inc. ("AIMM")
- -----------------------------------------------------------------------------------------------------------------------------------
(Last) (First) (Middle) 3. IRS or Social Se- 5. Relationship of Reporting Person(s) 6. If Amendment, Date
curity Number of to Issuer (Check all applicable) of Original
Reporting Person Director X 10% Owner (Month/Day/Year)
(Voluntary) ---- ----
Officer (give Other (specify ---------------------
title below) below) 7. Individual or
---- ---- Joint/Group Filing
(Check Applicable
227 West Monroe Street, Suite 4800 Line)
- ------------------------------------------------------------------------------------------------------------- Form filed by One
(Street) Reporting Person
---
Form filed by
More than One
X Reporting Person
Chicago IL 60606 ---
- -----------------------------------------------------------------------------------------------------------------------------------
(City) (State) (Zip) TABLE I -- NON-DERIVATIVE SECURITIES BENEFICIALLY OWNED
- -----------------------------------------------------------------------------------------------------------------------------------
1. Title of Security 2. Amount of Securities 3. Ownership 4. Nature of Indirect Beneficial
(Instr. 4) Beneficially Owned Form: Direct Ownership (Instr. 5)
(Instr. 4) (D) or Indirect
(I) (Instr. 5)
- -----------------------------------------------------------------------------------------------------------------------------------
Common Stock 1,694,100 (1) (1)
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. (Page 1 of 3)
* If the form is filed by more than one reporting person, SEE Instruction 5(b)(v). SEC 1474 (7-96)
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
- -----------------------------------------------------------------------------------------------------------------------------------
<S><C>
1. Name and Address of Reporting Person 2. Date of Event Re- 4. Issuer Name AND Ticker or Trading Symbol
quiring Statement
(Month/Day/Year)
BVF Partners L.P. December 16, 1999 Autoimmune Inc. ("AIMM")
- -----------------------------------------------------------------------------------------------------------------------------------
FORM 3 (CONTINUED) TABLE II - DERIVATIVE SECURITIES BENEFICIALLY OWNED (E.G., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE
SECURITIES)
- -----------------------------------------------------------------------------------------------------------------------------------
1. Title of Derivative Security 2. Date Exer- 3. Title and Amount of Securities 4. Conver- 5. Owner- 6. Nature of Indirect
(Instr. 4) cisable and Underlying Derivative Security sion or ship Beneficial
Expiration (Instr. 4) Exercise Form of Ownership
Date Price of Deriv- (Instr. 5)
(Month/Day/ Deri- ative
Year) vative Security:
-------------------------------------------------- Security Direct
Amount (D) or
Date Expir- or Indirect
Exer- ation Title Number (I)
cisable Date of (Instr. 5)
Shares
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
Explanation of Responses:
(1) The shares reported in this response are beneficially owned by BVF
Partners L.P., a Delaware limited partnership ("Partners"), the
designated filer of this joint filing on Form 3, and by its general
partner, BVF Inc., a Delaware corporation ("BVF Inc."), which is also an
investment advisor to Partners. Partners is the general partner of
Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF,
L.P.") and investment limited partnership which beneficially owns
1,109,625 of the shares of Common Stock reported in Table I. BVF, L.P.,
disclaims beneficial ownership of the 584,475 shares of Common Stock
reported in Table I beneficially owned by Partners on behalf of certain
managed investment accounts. Mark N. Lampert is the sole shareholder and
sole director of BVF, Inc., and is an officer of BVF, Inc. This joint
filing on Form 3 shall not be deemed an admission that Mark N. Lampert
is, for purposes of Section 16 of the Securities Exchange Act of 1934, as
amended, or otherwise, the beneficial owner of any equity securities
covered by this joint filing.
BVF Partners L.P.
By: BVF Inc., its general partner
12/ /99
------------------------------------- ---------------------
**Intentional misstatements or omissions of facts constitute Federal **Signature of Reporting Person Date
Criminal Violations. SEE 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
SEE Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB Number. (Page 2 of 3)
SEC 1474 (7-96)
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
- -----------------------------------------------------------------------------------------------------------------------------------
<S><C>
1. Name and Address of Reporting Person* 2. Date of Event Re- 4. Issuer Name AND Ticker or Trading Symbol
quiring Statement
(Month/Day/Year)
BVF Partners L.P. December 16, 1999 Autoimmune Inc. ("AIMM")
- -----------------------------------------------------------------------------------------------------------------------------------
Listing of the names and addresses of other reporting persons:
1. Biotechnology Value Fund, L.P. Biotechnology Value Fund, L.P.
227 West Monroe Street, Suite 4800
Chicago, Illinois 60606 By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT 12/22/99
------------------------------- --------
**Signature of Reporting Person
Authorized Signatory
2. BVF Inc. BVF Inc.
One Sansome Street, 39th Floor
San Francisco, California 94104 /s/ MARK N. LAMPERT 12/22/99
By: --------------------------------------------- --------
**Signature of Reporting Person Date
Authorized Signatory
3. Mark N. Lampert
One Sansome Street, 39th Floor
San Francisco, California 94104 /s/ MARK N. LAMPERT 12/22/99
By: --------------------------------------------- --------
**Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. (Page 3 of 3)
* If the form is filed by more than one reporting person, SEE Instruction 5(b)(v). 1474 (7-96)
</TABLE>
